BIIB Overview
Upcoming Projects (BIIB)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BIIB)
-
Quarterly Survey: Alzheimer's Disease and BIIB's Leqembi April 2024
Tickers: BIIB, LLY
Executed On: Apr 18, 2024 at 11:12 AM EDT -
Discussing Skyclarys in the commercial setting and ongoing trends in Friedreich's ataxia
Ticker: BIIB
Executed On: Feb 23, 2024 at 10:00 AM EST -
Exploring the Breakthroughs in Early Alzheimer's Disease: Discussing Leqembi with a Prescriber & Examining the TRAILBLAZER-ALZ 2 Phase 3 Study ahead of Early 2024 PDUFA Decision
Tickers: BIIB, LLY, ESALF, EII.XFRA
Executed On: Feb 22, 2024 at 02:30 PM EST -
Quarterly Survey: ALS Treatments and Biogen's Qalsody (tofersen) January 2024
Tickers: BIIB, Amylyx Pharmaceuticals, Mitsubishi Tanabe Pharma America
Executed On: Feb 16, 2024 at 04:27 PM EST -
Quarterly Survey: ALS Treatments and Biogen's Qalsody (tofersen) October 2023
Tickers: BIIB, Mitsubishi Tanabe Pharma America, AMLX
Executed On: Oct 31, 2023 at 11:41 AM EDT -
Quarterly Survey: ALS Treatments and Biogen's Qalsody (tofersen) August 2023
Ticker: BIIB
Executed On: Aug 28, 2023 at 04:03 PM EDT -
Digging into the results from the P3 CORAL study of Biogen and Sage Therapeutics' Zuranolone in patients with major depressive disorder before PDUFA on Aug 5th
Tickers: SAGE, BIIB
Executed On: Jul 18, 2023 at 01:00 PM EDT -
A Second Look: Digging into the Alzheimer's Landscape with a focus on Lilly's recent TRAILBLAZER-ALZ 2 Phase 3 study compared to Biogen's Leqembi
Tickers: LLY, BIIB
Executed On: May 18, 2023 at 04:30 PM EDT -
Digging into the Alzheimer's Landscape with a focus on Lilly's recent TRAILBLAZER-ALZ 2 Phase 3 study compared to Biogen's Leqembi
Tickers: LLY, BIIB
Executed On: May 04, 2023 at 02:00 PM EDT -
Discussing Biogen's Tofersen (BIIB067), an antisense drug being evaluated as a treatment for SOD1-ALS
Tickers: BIIB, IONS
Executed On: Feb 28, 2023 at 02:00 PM EST -
A Second View: Discussing Biogen/Eisai’s Lecanemab Phase 3 Clarity AD results in early Alzheimer's disease
Ticker: BIIB
Executed On: Oct 14, 2022 at 12:15 PM EDT
Free Project -
Discussing Biogen/Eisai’s Lecanemab Phase 3 Clarity AD results in early Alzheimer's disease
Ticker: BIIB
Executed On: Oct 04, 2022 at 05:00 PM EDT
Expired Projects (BIIB)
-
Understanding the Advances and Innovations in Diagnostics for Early Detection of Alzheimer's Disease.
Tickers: LLY-WD, BIIB, ESALF
Execute By: Feb 16, 2024 -
Discussing Biogen’s zuranolone following Phase 3 SKYLARK results in women with postpartum depression
Ticker: BIIB
Execute By: Jul 31, 2022 -
SURVEY: Understanding the potential impact of Risdiplam on Spinraza in SMA
Tickers: RHHBY, BIIB, NVS
Execute By: Mar 26, 2021 -
A Second View: Exploring the potential of FGEN's Pamrevlumab, GLPG1690 and BG00011 in Idiopathic Pulmonary Fibrosis
Tickers: FGEN, GLPG, GILD, BIIB
Execute By: Sep 27, 2019 -
Comparing Biogen's recently approved Spinraza to AveXis' pipeline drug AVXS-101 in treating spinal muscular atrophy
Tickers: BIIB, AVXS
Execute By: Aug 15, 2017 -
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016
Upcoming & Overdue Catalysts (BIIB)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BIIB)
-
FDA advisory committee rules Biogen's (BIIB) Alzheimer's ENGAGE drug trial of Aducanumab not enough to demonstrate effectiveness
Ticker: BIIB
Occurred on: Nov 06, 2020 -
Data from Biogen's (BIIB) Raxatrigine - BIIB074 (Nav1.7 inhibitor) in Painful Lumbosacral Radiculopathy (PLSR) due in 2018
Ticker: BIIB
Occurred on: Aug 15, 2018 -
Phase 2 data from Biogen's (BIIB) BAN2401 in Alzheimer’s disease due 2H 2018
Ticker: BIIB
Occurred on: Jul 25, 2018 -
New SPINRAZA (nusinersen) Data in Spinal Muscular Atrophy Unveiled at AAN Annual Meeting
Ticker: BIIB
Occurred on: Apr 23, 2018 -
Biogen (BIIB) Reports Top-Line Results from Phase 2b Study of Tysabri (Natalizumab) in Acute Ischemic Stroke
Ticker: BIIB
Occurred on: Feb 07, 2018 -
Eisai Alzheimer's Abeta BAN2401 Phase I/II data expected in mid 2017
Tickers: BIIB, EII.F
Occurred on: Dec 21, 2017 -
UnitedHealth (UNH) to Begin Coverage on April 1st for Ionis (IONS) and Biogen's (BIIB) Spinraza in Treatment of Spinal Muscular Atrophy (SMA)
Tickers: IONS, BIIB, UNH
Occurred on: Apr 01, 2017 -
PDUFA date for Ocrevus (Ocrelizumab) BLA in RMS and PPMS Pushed Back to March 28, 2017
Ticker: BIIB
Occurred on: Mar 29, 2017 -
U.S. Patent Trial and Appeal Board Upholds Biogen's (BIIB) 514 Patent Covering MS Drug Tecfidera (dimethyl fumarate)
Ticker: BIIB
Occurred on: Mar 21, 2017 -
Phase III data for SMN-RX in Type II spinal muscular atrophy patients expected in the first half of 2017
Ticker: BIIB
Occurred on: Jan 13, 2017 -
Solanezumab Phase III Alzheimer's data (EXPEDITION-3) expected year end 2016
Tickers: BIIB, LLY
Occurred on: Nov 23, 2016 -
Biogen (BIIB) and Ionis (IONS) Announce Phase 3 CHERISH Interim Results Evaluating SPINRAZA in Later-Onset Spinal Muscular Atrophy (SMA)
Tickers: IONS, BIIB
Occurred on: Nov 07, 2016 -
FDA and EMA Accept for Review Biogen's (BIIB) Marketing Application for Nusinersen in Treatment of Spinal Muscular Atrophy (SMA)
Ticker: BIIB
Occurred on: Oct 28, 2016 -
Biogen (BIIB) Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Tickers: BIIB, IONS
Occurred on: Sep 26, 2016 -
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation
Ticker: BIIB
Occurred on: Sep 01, 2016 -
SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency
Ticker: BIIB
Occurred on: Jul 17, 2016 -
Biogen and AbbVie’s Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
Tickers: BIIB, ABBV
Occurred on: Jul 05, 2016 -
Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Ticker: BIIB
Occurred on: Jun 07, 2016 -
FLIXABI, Biogen’s Infliximab Biosimilar Referencing Remicade, Approved in the European Union
Ticker: BIIB
Occurred on: May 30, 2016 -
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosis
Tickers: ABBV, BIIB
Occurred on: May 27, 2016 -
REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders
Tickers: RGNX, BIIB
Occurred on: May 16, 2016 -
Alprolix (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
Ticker: BIIB
Occurred on: May 13, 2016 -
Sobi and Biogen's Alprolix approved in Europe for hemophilia B
Ticker: BIIB
Occurred on: May 13, 2016 -
Biogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016
Ticker: BIIB
Occurred on: Jan 27, 2016 -
Ionis Pharmaceuticals earns 2.15M payment, on track for Phase 3 clinical Nusinersen trials
Tickers: IONS, BIIB
Occurred on: Jan 12, 2016
Strategic Initiatives (BIIB)
-
Biogen (BBIB) and Eisai (ESALY) launch late-stage study of BAN2401 in Alzheimer's
Ticker: BIIB
Announcement Date: Mar 22, 2019
